Literature DB >> 16879582

Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion.

Ulrich H M Spandau, Anna K Ihloff, Jost B Jonas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16879582     DOI： 10.1111/j.1600-0420.2006.00740.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN： 1395-3907


× No keyword cloud information.
  10 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: a pilot study.

Authors:  N J Shah; U N Shah
Journal:  Eye (Lond)       Date:  2011-02       Impact factor: 3.775

3.  Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion.

Authors:  Juan Carlos Mesa Gutiérrez; Luis Arias Barquet; Josep Maria Caminal; Sergi Prades Almolda; Nùria Planas Domènech; Octavi Pujol Goita; Marc Rubio Caso; Jorge Arruga Ginebreda
Journal:  Clin Ophthalmol       Date:  2008-12

4.  Intravitreal bevacizumab: an analysis of the evidence.

Authors:  Derrick P Smit; David Meyer
Journal:  Clin Ophthalmol       Date:  2007-09

5.  Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results.

Authors:  Julia Beutel; Focke Ziemssen; Matthias Lüke; Michael Partsch; Karl-Ulrich Bartz-Schmidt; Faik Gelisken
Journal:  Int Ophthalmol       Date:  2008-12-20       Impact factor: 2.031

6.  Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema.

Authors:  Rohit Shetty; Sivakami A Pai; Ajoy Vincent; Nitin Shetty; Kannan M Narayana; Babi Sinha; Bhujang K Shetty
Journal:  Doc Ophthalmol       Date:  2007-10-25       Impact factor: 2.379

7.  [OCT-guided reinjection of 2.5 mg bevacizumab for treating macular edema due to retinal vein occlusion].

Authors:  A E Höh; K B Schaal; A Scheuerle; F Schütt; S Dithmar
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

8.  Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study.

Authors:  Marilita M Moschos; Michael Moschos
Journal:  Doc Ophthalmol       Date:  2008-01-10       Impact factor: 2.379

9.  Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population.

Authors:  Atul Kumar; Subijay Sinha
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

10.  Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial.

Authors:  Ghader Motarjemizadeh; Miaad Rajabzadeh; Naser Samadi Aidenloo; Rohollah Valizadeh
Journal:  Electron Physician       Date:  2017-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.